Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

Launched by EMD SERONO RESEARCH & DEVELOPMENT INSTITUTE, INC. · May 27, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with metastatic or locally advanced solid tumors that cannot be surgically removed. The trial is looking at a medication called tuvusertib, both alone and in combination with other drugs, to find out how safe it is, the best dose to use, and whether it shows any signs of helping patients. It includes several parts that will test different combinations of drugs in various types of cancer, such as prostate, endometrial, and triple-negative breast cancer.

To be eligible for this trial, participants should have specific types of advanced cancers that have not responded to standard treatments or for which no standard treatment is appropriate. They should also have a good overall health status and a life expectancy of at least three months. During the trial, participants will receive the study medication and will be monitored closely for safety and effectiveness. This trial is currently recruiting participants, and it is an important opportunity for those who may not have other treatment options available.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Parts A1, A1.1, A1.2, A2, A3, and A2/3: Participants with metastatic or locally advanced unresectable solid tumors refractory to standard therapy or for which no standard therapy is judged appropriate by the Investigator, which may convey clinical benefit, or who cannot tolerate standard of care treatment
• • Parts A1.1 and A1.2: Triple negative breast cancer, epithelial ovarian cancer, castrate resistant prostate cancer, urothelial cancer, endometrial cancer, and colorectal cancer independent of mutation status.
• • Part A2: Participants with advanced prostate cancer whose tumor carries a genetic loss of function (LoF) mutation(s) in the gene ataxia telangiectasia mutated (ATM). No more than 3 prior lines of therapy for castrate resistant disease. Prior therapy must have included a taxane and a novel antiandrogen (example \[e.g.\] enzalutamide).
• • Part A3: Participants with advanced endometrial cancer whose tumor carries a genetic LoF mutation(s) in the gene AT-rich interaction domain 1A (ARID1A). Prior therapy must have included a platinum agent. Prior therapy must also have included a checkpoint inhibitor if the participant has mismatch repair (MMR)-deficient endometrial cancer. Note for Parts A2/A3: Participants with ATM LoF mutated prostate cancer and ARID1A LoF mutated endometrial cancer should be prioritized to the respective expansion arms instead of being enrolled in Part A1.1. The presence of ATM and ARID1A LoF mutations will be determined according to historic data collected prior to prescreening, generated by an assay with appropriate regulatory status, in either tumor or liquid biopsy. The Sponsor will confirm that mutations certified by historic data fulfil this definition.
• • Participants with eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, with estimated life expectancy of at least 3 months
• • Adequate hematological, hepatic, and renal function as defined in the protocol
• • Other protocol defined inclusion criteria could apply
• Exclusion Criteria:
• • Participants with any condition, including any uncontrolled disease state other than with metastatic or locally advanced unresectable solid tumors, that in the Investigator's opinion constitutes an inappropriate risk or a contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation
• • Participants with a known additional malignancy that is progressing and/or requires active treatment
• • Participants with carcinomatous meningitis are excluded regardless of clinical stability
• • Participants with serious gastrointestinal bleeding within 3 months, refractory nausea and vomiting, uncontrolled diarrhea, known malabsorption, significant small bowel resection or gastric bypass surgery, use of feeding tubes, other chronic gastrointestinal disease, and/or other situations that may preclude adequate absorption of oral medications
• • Participants with organ transplantation, including allogeneic stem cell transplant
• • Other protocol defined exclusion criteria could apply